Protocol Ledger

NCT04620330 · Phase II · COMPLETED

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Interventional Phase II clinical trial protocol NCT04620330 sponsored by Verastem in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-31 Enrollment: 90 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04620330
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04620330
Protocol FieldVerified Registry Value
NCT IdentifierNCT04620330
Consolidated Lead SponsorVerastem
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment90 participants (ACTUAL)
Registered Start Date2020-12-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI